Key result
Patients carrying the D allele of the ACE gene were 1.49 times more likely to develop essential hypertension compared to those carrying the I allele (OR 1.49).
Why the study?
Hypertension is rapidly increasing in Africa, but the evidence regarding the influence of angiotensin converting enzyme gene polymorphism on this pattern remains inconclusive.
Does ACE I/D gene polymorphism increase the risk of essential hypertension in African populations?
Meta-Analysis
Does ACE I/D gene polymorphism increase the risk of essential hypertension in African populations?
Odds Ratio: 1.49 (95% CI 1.07–2.07)
p-value: p=0.01
The ACE I/D gene polymorphism, specifically the D allele and DD genotype, is significantly associated with an increased risk of essential hypertension in African populations, particularly in Sub-Saharan Africa.
May support genetic risk assessment in hypertension; extends ACE I/D polymorphism evidence but requires validation before clinical adoption.
BACKGROUND: Hypertension is dramatically increasing in Africa with evidence of increased severity and resistance to treatment. Although angiotensin converting enzyme gene polymorphism is associated with higher prevalence of hypertension, the evidence is inconclusive on its influence on the emerging pattern in Africa. This meta-analysis is conducted to pool the available evidence to inform future research and interventions. METHODS: Articles published through May 2018 were systematically searched in PubMed, Scopus and EMBASE databases. Studies were assessed for inclusion by two independent researchers. Six models were used to assess the effect of angiotensin converting enzyme deletion-insertion gene polymorphism. Heterogeneity and publication bias were tested and sensitivity analysis was carried out. Odds ratio and 95% confidence intervals were measured for pooled effect. Both random effect and fixed effect models were used, whilst the frequency of DD, II and DI genotypes were computed and compared. RESULT: Patients with D allele were 1.49 times more likely to develop essential hypertension compared with patients who carry the I allele (OR:1.49; CI:1.07, 2.07). Similarly, patients who had homozygous co-dominance genotype DD (i.e., DD vs II) were at a 2.17 times higher risk of essential hypertension compared to the co-dominant genotype II (OR:2.17, CI:1.79, 3.18), dominant model (I.e., DD+ID vs II) (OR:1.48; CI:1.03, 2.12), and recessive model (OR:1.64; CI:1.03, 2.61). On subgroup analysis, participants from Sub-Saharan Africa were more genetically susceptible to hypertension compared to their North Africa counterparts. There was no publication bias found, but there was high to moderate heterogeneity. CONCLUSION: ACE I/D polymorphism is associated with essential hypertension in Africa in the allele contrast model, as well as the dominant, recessive and homozygous codominance model. On subgroup analysis, ACE I/D was associated with essential hypertension in patients from Sub-Saharan Africa but not in North Africa. A future large scale study, which includes different ethnic groups, is recommended.
No takes yet. Share an insight, caveat, or question.
Mengesha et al. (2019) conducted a meta-analysis in Essential hypertension. Angiotensin converting enzyme (ACE) D allele vs. ACE I allele was evaluated on Essential hypertension (OR 1.49, 95% CI 1.07, 2.07, p=0.01). Patients carrying the D allele of the ACE gene were 1.49 times more likely to develop essential hypertension compared to those carrying the I allele (OR 1.49).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: